中科微点-全球专利检索

  1. Login
  2. Sign Up
Invention Grant
US08097704B2 Antibody specifically binding to DR5 and composition for preventing or treating cancers comprising the same 有权
与DR5特异性结合的抗体和用于预防或治疗包含其的癌症的组合物

Antibody specifically binding to DR5 and composition for preventing or treating cancers comprising the same
Abstract:
The present invention provides an antibody specifically binding to death receptor 5 (DR5), which is selected from the group consisting of: an antibody comprising a heavy chain variable region (VH) having the amino acid sequences of SEQ ID NOs: 1 to 3 at complementary determining regions (CDRs) and a light chain variable region (VL) having the amino acid sequences of SEQ ID NOs: 4 to 6 at CDRs; and an antibody comprising a (VH) having the amino acid sequences of SEQ ID NOs: 7 to 9 at CDRs and a (VL) having the amino acid sequences of SEQ ID NOs: 10 to 12 at CDRs, and a composition for preventing or treating a cancer comprising the same. The antibody of the present invention can be effectively used for the prevention or treatment of various cancers, through inducing autophagic cell death of TRAIL-sensitive cancer cells as well as TRAIL-resistant cancer cells by specific binding to DR5.
Abstract(Chinese):

本发明提供了特异性结合死亡受体5（DR5）的抗体，其选自：包含具有SEQ ID NO：1至3的氨基酸序列的重链可变区（VH）的抗体， 互补决定区（CDR）和在CDR中具有SEQ ID NO：4至6的氨基酸序列的轻链可变区（VL）; 以及抗体，其包含CDR上具有SEQ ID NO：7至9的氨基酸序列的氨基酸序列的抗体和在CDR中具有SEQ ID NO：10至12的氨基酸序列的（VL），以及用于预防或 治疗包含该癌症的癌症。 通过特异性结合DR5，本发明的抗体可以通过诱导TRAIL敏感性癌细胞的自噬细胞死亡以及抗TRAIL抗性癌细胞，有效地用于预防或治疗各种癌症。

Public/Granted literature
Information query
Espacenet
Patent Agency Ranking
0/0